<DOC>
	<DOCNO>NCT00896051</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics ( body absorbs , distributes , metabolize eliminates drug ) ( PK ) ETR give ATV/rtv 1 NRTI treatment experience HIV-1 infected patient . In addition , safety , tolerability anti-HIV effect regimen also study . A total 46 patient enrol .</brief_summary>
	<brief_title>TMC125-TiDP2-C238 : An Exploratory Pharmacokinetics , Safety Anti-HIV Activity Study Etravirine ( ETR ) When Given With Boosted Atazanavir ( ATV/Rtv ) Two Different Doses 1 Nucleoside Reverse Transcriptase Inhibitor ( NRTI ) Treatment Experienced HIV Patients</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , exploratory , open-label ( involved people know identity intervention ) trial evaluate pharmacokinetics ( PK ) , safety , tolerability anti-HIV ( anti Human Immunodeficiency Virus ) activity etravirine ( ETR ) give atazanavir/ritonavir ( ATV/rtv ) 1 nucleoside reverse transcriptase inhibitor ( NRTI ) 46 treatment experience HIV-1 infected patient . The trial consist : 4 week Screening Period , 2 week Pre-Treatment Phase , 48-week Treatment Period , Final Visit follow 4-week Follow-up Period ( patient continue treatment ETR another trial program ) . Safety evaluation ( AE reporting , lab , vital sign , etc . ) monitor study visit . A PK substudy ( include protocol , optional participation ) tenofovir ( TDF ) add antiretroviral regimen 7 day conduct patient &gt; 24 week treatment suppress HIV-1 viral load . In Pre-Treatment Phase , patient receive ATV/rtv 300/100 mg daily take follow meal morning + 2 NRTIs ( dose specify label ) 14 day . In Treatment Phase , patient receive ETR 200 mg twice daily addition ATV/rtv ( 300/100 mg 400/100 mg ) daily meal + 1 investigator-selected NRTI 48 week . In substudy TDF 300 mg daily add treatment regimen x 7 day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Documented HIV1 infection Failing stable ART ( anti retroviral therapy ) HIV1 plasma viral load 500 HIV1 RNA copies/ml Presence least 1 documented NNRTI mutation Demonstrated sensitivity ATV , ETR least one select NRTIs base resistance test screen General medical condition , investigator 's opinion , interfere assessment completion trial Substudy : patient treat C238 24 week currently suppress ( defined patient least 2 recent consecutive viral load le 50 cp/mL ) consider eligible substudy Primary HIV1 infection Previously document HIV2 infection Previously fail 2 HIV PIcontaining regimens Previous diagnosis hereditary hyperbilirubinemia ( eg . Gilbert 's syndrome , CriglerNajjar syndrome ) . Grade 3 4 toxicity ( accord DAIDS grading ) Acute chronic viral hepatitis Receipt investigational drug investigational vaccine within 30 day prior trial drug administration Pregnant breastfeed female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>TMC125-TiDP2-C238</keyword>
	<keyword>TMC125-C238</keyword>
	<keyword>Etravirine</keyword>
	<keyword>Intelence</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>